Would you begin by explaining to the readers of Pharmaceutical Executive the importance of the operation in Poland for the company? Indeed Poland because of largest…
In Conversation
Firstly, what attracted you to join the CRO industry with Quintiles over 10 years ago? I had been working for 5 years as a doctor in…
Mr. Medda, Teva’s Italian history is relatively young, could you describe the main facts that describe Teva presence in Italy? Teva Italia was founded in 1996…
As we are just starting 2011, could you share with us the results of Nycomed Poland in 2010? In 2010, the affiliate has not been as…
When we look at the full year 2010 unaudited IFRS consolidated sales, we see that Ipsen performed very well in 2010 in Central and Eastern Europe.…
You joined Eli Lilly Poland in November 2008 as a Marketing Director and you have been leading the affiliate since January 2010. Moreover you are co-chairing…
The pharmaceutical industry market growth, including generics and originator drugs, is today steady and sustainable, approximating 10% year on year. The market size is over five…
In the pharma world, managers change frequently from one company to another, and this phenomenon has been accelerated with the consolidation of the market, however you…
Until very recently originator drugs had a very weak presence in central and east European countries including Poland, and there was no real patent legislation. Nevertheless,…
Dr. Zörner, can you please begin by introducing our readers to the CAFF (Czech Association of Pharmaceutical Firms), and explicate its key activities and mission? We…
Mr. Březovký, can you begin with an introduction to SUKL and its role within the Czech Republic’s complex regulatory environment? I would like to begin by…
In the Czech Republic, homeopathic medicines were prohibited during the communistic period, but found resurgence after 1989. Can you give us an overview of the development…
